GANX Insider Trading Activity and SEC Form 4 Filings
GANX insider trading summary
No open-market insider purchases or sales of Gain Therapeutics, Inc. (GANX) have been reported on SEC Form 4 in the past 12 months.
Latest GANX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 9, 2024 | Gene Mack | CFO and Interim CEO | Buy | $15K (14,400 @ $1.01) |
| Aug 9, 2024 | Khalid Islam | Executive Chairman | Buy | $50K (50,000 @ $1.00) |
| Jul 1, 2024 | Eric I Richman | Director | Buy | $15K (12,000 @ $1.21) |
| Jul 1, 2024 | Eric I Richman | Director | Buy | $6K (5,000 @ $1.23) |
| Mar 28, 2024 | Jeffrey Scott Riley | Director | Buy | $116K (30,000 @ $3.86) |
| Dec 21, 2023 | Matthias Alder | Chief Executive Officer | Sell | $507 (206 @ $2.46) |
| Dec 7, 2023 | Matthias Alder | Chief Executive Officer | Sell | $5K (1,820 @ $2.50) |
| May 25, 2022 | Eric I Richman | Chief Executive Officer | Buy | $6K (2,482 @ $2.58) |
| May 20, 2022 | Eric I Richman | Chief Executive Officer | Buy | $26K (9,256 @ $2.83) |
| May 19, 2022 | Salvatore Calabrese | Chief Financial Officer | Buy | $24.3M (3,000 @ $8100.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.